

Supplementary Table 3. Serum levels of ALT, MMPs, TIMPs, and SDF-1 α in NASH patients before and after two months of pioglitazone administration

	ALT (IU/L)	MMP-1 (pg/mL)	MMP-2 (ng/mL)	MMP-9 (ng/mL)	TIMP-1 (ng/mL)	TIMP-2 (ng/mL)	SDF-1 α (pg/mL)
F1 Before PZN	56 \pm 41	2.09 \pm 0.66	25.3 \pm 19.6	16.5 \pm 14.0	127.8 \pm 17.8	76.3 \pm 21.4	172.3 \pm 81.3
	37 \pm 22	1.64 \pm 0.80	27.3 \pm 14.0	12.5 \pm 8.2	127.5 \pm 12.6	83.8 \pm 24.9	278.7 \pm 176.5
F2 Before PZN	51 \pm 31	0.85 \pm 0.48	25.0 \pm 7.2	20.0 \pm 21.0	126.6 \pm 22.4	62.2 \pm 13.0	307.4 \pm 254.0
	35 \pm 16	0.82 \pm 0.59	19.3 \pm 10.6	11.9 \pm 8.5	115.6 \pm 18.1	64.3 \pm 14.0	317.5 \pm 139.9
F3 Before PZN	64	1.31	33.8	38.0	239.3	146.4	317.8
	13	0.57	24.6	6.5	174.2	104.1	203.1
F4 Before PZN	79	0.51	26.6	8.8	169.7	79.1	110.6
	111	0.10	45.7	59.1	190.1	76.4	357.7

Values indicate mean \pm standard deviation (SD). Number of patients: NASH F1 (n=6), NASH F2 (n=9), NASH F3 (n=1), NASH F4 (n=1).

ALT, alanine aminotransferase; MMP, matrix metalloproteinase; TIMP, tissue inhibitors of metalloproteinase; SDF, stromal cell-derived factor; NASH, nonalcoholic steatohepatitis; PZN, pioglitazone; F, fibrosis.